Words by Jade Williams
Sanofi is set to acquire Blueprint Medicines, a US-based biopharmaceutical company specialising in systemic mastocytosis and other KIT-driven diseases.
The acquisition, valued at approximately $9.1bn, aims to strengthen Sanofi’s rare disease and immunology pipeline. Blueprint’s lead asset is the first and only therapy approved in both the US and Europe for advanced and indolent systemic mastocytosis.
“We are excited to welcome Blueprint’s talented people and we look forward to chasing the miracles of science together,” said Paul Hudson, CEO, Sanofi. “This makes sense for science, for both companies, for healthcare professionals, and – most of all – for patients.”
The acquisition is expected to complement Sanofi’s immunology strategy by leveraging Blueprint’s well-established relationships with dermatologists, allergists and immunologists.
Kate Haviland, CEO, Blueprint Medicines, noted that Sanofi’s “exceptional leadership in rare disease and immunology” and “proven ability to solve medical challenges at scale” stand to accelerate her company’s mission to bring life-changing medicines to more patients globally.
This is another significant acquisition for Sanofi, which recently agreed to acquire Vigil Neuroscience for $470m.
